discontinue sulfonylurea when starting glp-1 receptor agonist agonists for individualized treatment of type 2 diabetes mellitus Glucagon-like peptide-1 receptor: mechanisms and

doi: 10.1139/bcb-2021-0365 62 YangYZhouYWangYWeiXWuLWangTet al

Being among the first to offer reduced serving sizes can mitigate any revenue impact of reduced volumes

Metabolic dysfunction-associated steatotic liver disease (formerly called NAFLD) affects roughly 30% of adults globally and has no approved pharmacotherapy

515,516,517 GLP-1 may improve the livers antioxidant capacity and metabolic function by activating Sirt1, thereby helping to alleviate the pathological changes associated with NASH

As the confounding structure for the head-to-head comparison of tirzepatide versus semaglutide was expected to be more similar to the tirzepatide versus dulaglutide benchmarking study, we proceeded with the prespecified analysis plan that included death in the primary composite MACE outcome

& Ambery, P